FDA's NDA And BLA Approvals: Fiasp, Ascor
Executive Summary
Original new drugs and biologics approved by US FDA.
You may also be interested in...
Lilly’s Ultra Rapid Lispro Mealtime Insulin Sails Through Phase III, But Will It Be Enough?
With only slight potential advantages in some types of patients, ultra-rapid insulins will likely still need to compete on price to be more widely successful, analysts say.
Novo Nordisk’s Ultra Fast-Acting Insulin On Course To Indian Debut
Novo Nordisk is gearing towards the potential launch of its ultra fast-acting insulin aspart, Fiasp, in India. Pricing and how the product will be positioned alongside NovoRapid (conventional insulin aspart) are expected to be closely watched by competition.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.